-
121.发明申请公开(公告)号：US20190210998A1
公开(公告)日：2019-07-11
申请号：US16306751
申请日：2017-06-02
Inventor： Hong Liu , Jia Li , Wei Zhu , Yubo Zhou , Jiang Wang , Mingbo Su , Shuni Wang , Wei Xu , Chunpu Li , Weijuan Kan , Hualiang Jiang , Kaixian Chen
IPC: C07D403/12 , A61P35/00 , C07D209/08 , C07D405/12 , C07D401/12 , C07D215/58
CPC classification number: C07D403/12 , A61P35/00 , C07D209/04 , C07D209/08 , C07D215/00 , C07D215/58 , C07D401/12 , C07D405/12 , Y02P20/55
Abstract: The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.
-
公开(公告)号：US20190201543A1
公开(公告)日：2019-07-04
申请号：US16326886
申请日：2017-06-09
Applicant: FUDAN UNIVERSITY , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , SHANGHAI MIRACOGEN INC.
Inventor： Ke Yu , Jingkang Shen , Tao Meng , Lanping Ma , Xuesai Zhang , Qingrou Li
IPC: A61K47/68 , C07K16/36 , A61K47/54 , A61K31/40 , A61K31/4025 , A61K31/5365 , A61P35/00
CPC classification number: A61K47/6803 , A61K31/40 , A61K31/4025 , A61K31/5365 , A61K31/537 , A61K47/542 , A61K47/545 , A61K47/68 , A61K47/6843 , A61P35/00 , C07K16/36 , C07K2317/24 , C07K2317/565 , C07K2317/90
Abstract: A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.
-
公开(公告)号：US10259798B2
公开(公告)日：2019-04-16
申请号：US15301265
申请日：2015-02-09
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES , SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD.
Inventor： Lijiang Xuan , Yiping Wang , Weibin Song , Chunguang Chen , Dingxiang Li , Xiaoyu Zhou , Yunlong Gu , Liang Hu , Jing Zhao , Wenwei Xu , Shumei Wang
IPC: A61K36/00 , C07D307/86 , A61K31/343 , A61K36/537
Abstract: The present invention relates to a method for preparing magnesium lithospermate B. The method is characterized in that: magnesium lithospermate B is extracted or purified from a Salvia miltiorrhiza plant material or a Salvia miltiorrhiza extract in the presence of an added magnesium salt. The present invention also relates to a high-purity magnesium lithospermate B product prepared by the method of the present invention, wherein the content of magnesium lithospermate B is more than 95% by weight.
-
公开(公告)号：US10167299B2
公开(公告)日：2019-01-01
申请号：US15109101
申请日：2014-12-29
Inventor： Hong Liu , Beili Wu , Yongtang Zheng , Xin Xie , Hualiang Jiang , Panfeng Peng , Ronghua Luo , Jing Li , Jian Li , Ya Zhu , Ying Chen , Haonan Zhang , Liumeng Yang , Yu Zhou , Kaixian Chen
IPC: C07D519/00 , C07D409/14 , C07D451/04 , C07D401/14 , A61K45/06 , A61K31/46 , A61K31/4545 , A61K31/454
Abstract: Provided are 1-(3-aminopropyl) substituted cyclic amine compounds as represented by frmula (I), pharmaceutically acceptable salts, enantiomers, diastereoisomers, racemates and mixtures thereof, and a method of synthesizing said 1-(3-aminopropyl) substituted cyclic amine compounds by using aromatic heterocyclic formaldehyde as raw material. Said compounds can be used as CCR 5 antagonist for the treatment of HIV infection.
-
公开(公告)号：US20180305390A1
公开(公告)日：2018-10-25
申请号：US15738675
申请日：2016-06-23
Inventor： Hong LIU , Jia LI , Jiang WANG , Jingya LI , Hui CHEN , Dan LI , Jian LI , Yibing WANG , Hualiang JIANG , Kaixian CHEN
CPC classification number: C07H19/01 , A61K31/35 , A61K31/381 , A61K31/427 , A61K31/4436 , A61P3/08 , C07D493/10
Abstract: C, O-spiro aryl glycoside compounds are provided. Specifically provided are C, O-spiro aryl glycoside compounds represented by the formula (I), wherein the definitions of each variable group are described in the specification. Also provided are methods of preparing and using the C, O-spiro aryl glycoside compounds. The C, O-spiro aryl glycoside compounds can be used as SGLT2 inhibitors and for treating diseases, such as diabetes, atherosclerosis, and adiposity.
-
Patent Agency Ranking
公开(公告)号：US20180222904A1
公开(公告)日：2018-08-09
申请号：US15763095
申请日：2016-10-03
Applicant: Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. , SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventor： Xibin LIAO , Jia LI , Zhijian LU , Yubo ZHOU , Anhui GAO
IPC: C07D471/04 , A61K45/06 , A61K31/437 , A61K31/56 , A61K31/4545 , A61K31/5377 , A61K31/501 , A61K31/519 , A61K31/42
CPC classification number: C07D471/04 , A61K31/4184 , A61K31/42 , A61K31/437 , A61K31/4545 , A61K31/501 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K31/56 , A61K45/06 , A61P29/00 , A61P35/00 , C07D235/22 , C07D473/34 , C07D487/04
Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
-
公开(公告)号：US20180079749A1
公开(公告)日：2018-03-22
申请号：US15561003
申请日：2016-03-24
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA,CHINESE ACADEMY OF SCIENCES , SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.
Inventor： Jingkang SHEN , Tao MENG , Ting YU , Lanping MA , Xin WANG , Lin CHEN
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Provided is a process of synthesizing a substituted pyridine and pyrimidine compound. Particularly, provided is a method for preparing a compound of formula III via a compound of formula II′, wherein the definition of each of groups is as described as the description. Compound with other methods, the method in the present invention has features of high yield and a result product being easier to separate.
-
公开(公告)号：US09914707B2
公开(公告)日：2018-03-13
申请号：US15120771
申请日：2015-02-15
Inventor： Wenhu Duan , Jian Ding , Yongcong Lv , Hua Xie
IPC: C07D231/56 , C07D261/20 , C07D413/12 , C07D401/12 , C07D491/048 , C07D495/04
CPC classification number: C07D231/56 , C07D261/20 , C07D401/12 , C07D413/12 , C07D491/048 , C07D495/04
Abstract: The present invention relates to a naphthylamide compound of the structure as represented by formula (I), medicinal salts, prodrugs and hydrates or solvates thereof, and also relates to a method of preparing the compounds, pharmaceutical compositions comprising the compounds and the uses thereof as protein tyrosine kinase inhibitors, particularly as VEGFR-2 inhibitors, in preparing drugs for preventing and treating diseases related to abnormal angiogenesis.
-
公开(公告)号：US20170158680A1
公开(公告)日：2017-06-08
申请号：US15124264
申请日：2015-03-09
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES , SUZHOU VIGONVITA LIFE SCIENCES CO., LTD. , TOPHARMAN SHANDONG CO., LTD.
Inventor： Hualiang JIANG , Zhen WANG , Jianfeng LI , Rongxia ZHANG , Yang HE , Yongjian LIU , Minghao BI , Zheng LIU , Guanghui TIAN , Weiming CHEN , Feipu YANG , Chunhui WU , Yu WANG , Xiangrui JIANG , Jingjing YIN , Guan WANG , Jingshan SHEN
IPC: C07D409/12 , C07D495/04 , C07D471/04
CPC classification number: C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D495/04 , C07D519/00
Abstract: The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.
-
公开(公告)号：US20170137399A1
公开(公告)日：2017-05-18
申请号：US15301265
申请日：2015-02-09
Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES , SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD.
Inventor： Lijiang Xuan , Yiping Wang , Weibin Song , Chunguang Chen , Dingxiang Li , Xiaoyu Zhou , Yunlong Gu , Liang Hu , Jing Zhao , Wenwei Xu , Shumei Wang
IPC: C07D307/86
CPC classification number: C07D307/86 , A61K31/343 , A61K36/537
Abstract: The present invention relates to a method for preparing magnesium lithospermate B. The method is characterized in that: magnesium lithospermate B is extracted or purified from a Salvia miltiorrhiza plant material or a Salvia miltiorrhiza extract in the presence of an added magnesium salt. The present invention also relates to a high-purity magnesium lithospermate B product prepared by the method of the present invention, wherein the content of magnesium lithospermate B is more than 95% by weight.
-
-
-
-
-
-
-
-
-
Search Results
257
records
(took 0.038 seconds)
